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Abstract: The increasing number of opioid users among chronic pain patients, and opioid 
abusers among the general population, makes perioperative pain management challenging for 
health care professionals. Anesthesiologists, surgeons, and nurses should be familiar with some 
pharmacological phenomena which are typical of opioid users and abusers, such as tolerance, 
physical dependence, hyperalgesia, and addiction. Inadequate pain management is very common 
in these patients, due to common prejudices and fears. The target of preoperative evaluation is 
to identify comorbidities and risk factors and recognize signs and symptoms of opioid abuse 
and opioid withdrawal. Clinicians are encouraged to plan perioperative pain medications and 
to refer these patients to psychiatrists and addiction specialists for their evaluation. The aim of 
this review was to give practical suggestions for perioperative management of surgical opioid-
tolerant patients, together with schemes of opioid conversion for chronic pain patients assum-
ing oral or transdermal opioids, and patients under maintenance programs with methadone, 
buprenorphine, or naltrexone.
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Introduction
Perioperative management of patients who have been exposed to long-term opioids, 
whether of therapeutic or recreational origin, is a challenging issue for anesthesiolo-
gists. This population is increasing, because in most developed countries, the number 
of patients for whom opioids are prescribed on a long-term basis has grown rapidly 
over the last decade. In the USA, sales of prescription opioids have quadrupled in the 
last 15 years, leading to one out of five patients with chronic nonmalignant pain being 
under treatment with opioids.1 The wide use of these drugs has led to an increase in 
prescribed opioid abusers, estimated to be nearly 2 million in the USA. Over 90 Ameri-
cans die every day from an opioid overdose. The opiates commonly abused include 
prescription opioids, being oxycodone and hydrocodone, which are most commonly 
involved in overdose death; illicit drugs like heroin; and de-addiction opioids like 
methadone and buprenorphine.2
Conversely, European countries are still far away from the prescription opioid 
market that is observed in the USA.3 Therefore, nowadays, the prevalence of opi-
oid abusers among chronic pain patients seems to be significantly lower in Europe, 
compared with the USA; however, the risk cannot be excluded.4 According to the 
European Drug Report 2016, in Europe in 2014, the average prevalence of high-risk 
opioid users among adults (aged 15–64 years) was estimated at 0.4%, the equivalent 
of 1.3 million. Opioids have been found in 82% of fatal overdoses, mostly in the 
north of Europe, probably related to an increase in new heroin uptake and changing 
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drug consumption patterns, particularly the increased use of 
synthetic opioids.5,6 According to the European Monitoring 
Centre for Drugs and Drug Addiction, high-risk drug use 
includes any “drug use that is causing actual harms (nega-
tive consequences) to the person (including dependence, 
but also other health, psychological or social problems) or 
is placing the person at a high probability/risk of suffering 
such harms.” In Italy, in 2014, the latest estimate suggested 
that there were 203,000 high-risk drug users, corresponding 
to a rate of 5.16 per 1,000 inhabitants aged 15–64 years and 
over 75,000 clients in a substitution treatment. A decline 
in the estimated number of high-risk opioid users that was 
noted from 2008 onwards stopped in 2014, when a notice-
able increase was seen.7
These epidemiological data explain why anesthesi-
ologists, surgeons, and all health care professionals (HCPs) 
involved in perioperative management are likely to encounter 
with increasing probability in their clinical practice opioid 
users and abusers who require surgical treatment and 
adequate perioperative analgesia. Opioids are the mainstay 
of an effective analgesia after surgery, for the management 
of moderate to severe pain, along with regional techniques.8 
However, their use may result in being extremely challeng-
ing in these patients.
The aim of this narrative review was to give a clinical 
perspective of the perioperative management of opioid-
tolerant patients.
Tolerance, physical dependence, 
hyperalgesia, and addiction to 
opiates
Our first suggestion for HCPs is to be familiar with some 
pharmacological phenomena that are typical of the opioid 
treatment.
Tolerance and physical dependence can happen after 
chronic exposure to many drugs, including opiates. Tolerance 
is the decrease of the pharmacological effect occurring after 
repeated administration of opioid receptor agonists, that is, 
the body adapts to the drug and requires increased doses to 
achieve a certain effect.9
These changes in body homeostasis lead to physical 
dependence, a state of neuro-adaption to a specific opioid, 
characterized by the withdrawal crisis if the agonist admin-
istration is abruptly discontinued. These two phenomena 
are therefore related to each other and independent from 
the psychic dependence, also named addiction, but often 
accompany it.
It is now believed that neuronal adaptation phenomena 
to the chronic effects of opiates occur, involving a complex 
series of molecular and cellular events, including receptor 
desensitization, downregulation, and internalization.9
Conversely, drug addiction is defined as a chronic, relaps-
ing brain disease, characterized by compulsive illegal drug 
seeking and use, despite harmful consequences.10 Biological/
genetic and environmental factors may increase the vulner-
ability to addiction, particularly in early adolescence.11
A therapeutically appropriate use of opiates for the treat-
ment of chronic pain has been hindered to date by the 
incorrect belief that their use will inevitably lead to the 
psychic dependence. The actual prevailing hypothesis sug-
gests that the therapeutic use of opiates does not affect the 
conditioning environmental stimuli, which are so important 
in determining the positive reinforcement that leads to the 
compulsive use. The condition in which the drug is taken, 
and especially the underlying painful disease, do not pro-
vide the substrate and the context in which the patient seeks 
for the drug; clinical findings in the field of pain confirm 
that the phenomenon of abuse is observed very rarely.4,12 
Recent neurobiological studies in animal models suffering 
from neuropathic pain and treated with opioids showed a 
decrease in dopamine production and the “reward effect” 
typical of drug addiction.13
Opiates produce strong analgesia, but sometimes their 
use is limited by an increased paradoxical hypersensitivity, 
known as opioid-induced hyperalgesia (OIH), in some cases 
associated with tolerance.14 Cellular and molecular mecha-
nisms underlying OIH include genetic differences, variants 
of mu opioid receptor (MOR), neurons and glia factors, 
long-term potentiation, neuronal sensitization, and neuroin-
flammation. Recently, it has been proposed that epigenetic 
mechanisms, such as DNA hyper-methylation and histone 
deacetylases, might be responsible for OIH, leading to a 
novel approach in pain therapy by means of drugs acting on 
epigenetic targets, such as l-acetylcarnitine.14
Preoperative evaluation and 
identification of population at risk
During preoperative evaluation, anesthesiologists, in their 
practice, are likely to encounter an increasing number of 
opioid users and abusers, which presents a wide array of 
challenges. The main value of preoperative assessment is 
the opportunity for anesthesiologists to identify risk factors 
and reduce the patients’ surgical and anesthetic perioperative 
morbidity or mortality.15
A few key points are essential for preoperative manage-
ment of these subjects:
1. Always consider this key question: “Is my patient an 
opioid user or abuser?”
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True abusers should be promptly detected, while 
opioid users should not be wrongly labeled as addicted. 
Table 1 may help anesthesiologists to detect the clinical 
differentiation of opioid-dependent patients, between 
opioid users for chronic pain and opioid abusers.16
2. In opioid users/abusers obtain details of the type of 
opioid, the duration of use/abuse, and the timing of the 
last dose.17
Patients suffering from opioid addiction may give 
false history during pre-anesthetic check-up. Particularly, 
anesthesiologists should consider their privacy and the 
reluctance to speak in front of their parents, for young 
people.
Not all opioids have the same abuse potential, 
depending on their ability to release dopamine from the 
nucleus accumbens, and pharmacokinetics (PKs).18 Imme-
diate release formulations may have a higher risk.
3. Recognize signs and symptoms of opioid abuse and 
opioid withdrawal as soon as possible (Table 2).
Consider time of the last dose. Withdrawal symptoms 
will occur upon abrupt discontinuation of opioids or when 
opioid antagonists are administered. Acute withdrawal 
timeframes vary for specific substances, according to their 
PKs: 6–18 hours for morphine and heroine; 24–48 hours 
for methadone. Protracted or chronic withdrawal refers 
to the presence of symptoms that persist beyond the 
generally expected acute withdrawal, probably caused 
by adaptive changes in the central nervous system (CNS) 
that lead to affective changes. For elective surgery, opioid 
users should be encouraged to take their usual dose of 
prescribed opioid on the morning of surgery.
4. Identify population at risk.
Unfortunately, patients may deliberately omit to 
declare the use of opioids. Identifying opioid-consuming 
patients is essential for their adequate perioperative 
management. Different tools have been proposed for 
identifying potential opioid abusers, particularly for 
subjects suffering from chronic pain, at the beginning 
of treatment with opioid analgesics, but no one has 
been conceived to identify the evaluation of indirect 
factors of drug abuse.19 The Addiction Risk Question-
naire has been proposed as a 28-item tool, specifically 
designed for the detection of patients with high measur-
able score of vulnerability to drug addiction.20 Nicotine 
addiction, alcohol dependence, and psychiatric history 
are significantly considered the most relevant risk 
factors. Preoperative opioid use has been associated 
with a potentially increased risk for opioid misuse after 
surgery.21 Therefore, this vulnerable patient population 
may require a closer follow-up and early referral to 
appropriate specialists when needed.
5. Obtain comprehensive assessment including history, 
physical examination, and review diagnostic studies.
Patients with opioid abuse and dependence undergo-
ing elective surgery have increased risk of postoperative 
mortality and morbidity, including surgical site infec-
tions, mental disorders, respiratory failure, pneumonia, 
mechanical ventilation, myocardial infarction, and 
gastrointestinal events. Preoperative opioid misuse was 
also associated with prolonged hospital length of stay 
and increased resource utilization.22
6. Evaluate common comorbidities in addicted patients.23
•	 Cardiovascular disease: hypertension, dilated 
cardiomyopathy.
•	 Gastrointestinal disease: reduced gastrointestinal 
motility, gastroesophageal reflux disease (GERD), 
which increases the risk of aspiration during orotra-
cheal intubation, dysphagia, constipation, and bowel 
discomfort.
•	 Infectious disease: hepatitis, human immunodefi-
ciency virus, sexually transmitted disease.
•	 Difficult vein access.
Table 1 Clinical differentiation between opioid users for chronic 
pain and opioid abusers
Opioid users for 
chronic pain
Opioid abusers
Use of opioids Appropriate Out of control
Declared Often deliberately omitted
Quality of life improved by opioids impaired by opioids
Awareness of opioid-
related side effects
Complete Unconcerned
Diagnosis Available Unavailable
Treatment plan and 
medical prescription
Followed Unavailable
Opioid medication Available Hidden, illicit
Table 2 Signs and symptoms of opioid abuse and opioid withdrawal
Opioid abuse Opioid withdrawal
vomiting Dysphoric mood
Pruritus Nausea or vomiting
Sweating Lacrimation
Twitching Rhinorrhea
Miosis (contracted pupils) Muscle aches
Loss of appetite Pupillary dilation
Drowsiness Piloerection
Respiratory depression Sweating
Coma Diarrhea
Needle marks Yawning
Fever
insomnia
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•	 Concomitant drug abuse (anxiolytics, benzodiaz-
epines, alcohol).
 7. Consider possible coexisting psychiatric disorders 
(depression, anxiety, psychosis, and personality 
disorders).24
Some patients with complicating medical and social 
conditions may require integrated care with behavioral 
health specialists. Consider referral to psychiatrists and 
addiction specialists for their evaluation.
 8. Avoid prejudices and assure the patient.
 9. Keep in mind patients’ fears.
Opioid-dependent patients may fear the risks 
of under-treatment due to prejudices, dependence 
relapse, and ability self-administering analgesia by 
patient-controlled analgesia (PCA). Consider patients’ 
expectations related to postoperative pain management, 
and investigate the possible correlation with previous 
experiences. Patients should be reassured that despite 
a previous or an ongoing history of opioid dependency, 
effective pain control is an achievable goal. Risk of 
relapses can be minimized.
 10. Plan perioperative pain medication.
•	 Investigate effective management strategies used in 
previous procedures.
•	 Consider acetaminophen, non-steroidal anti- 
inflammatory drugs (NSAIDs) or selective COX-2 
inhibitors as preoperative medication.
•	 Discuss with the patient the analgesic strategy 
(multimodal approach, regional techniques when 
suitable, PCA).
•	 Document treatment plan with a written opioid pain 
care agreement with the patient.25
Prejudice and misconceptions that 
limit postoperative pain treatment 
in opioid-tolerant patients
Patients on chronic opioids are at risk of receiving inadequate 
analgesia because of clinicians’ misconceptions about opioids 
or prejudice toward patients addicted to opioids.26
Recent warning on the risk of abuse among opioid users 
in chronic non-cancer pain, including the Center for Disease 
Control and individual state guidelines, have generated 
a sort of opiophobia. Addiction is commonly perceived 
as a crime rather than a disease; therefore, these patients 
are stigmatized for their opioid use. Consequently, when 
asked for more opioids to relieve pain, they are seen under 
suspicion and perceived as drug-seeking. These patients are 
more demanding than others because of fear that their pain 
will be under-treated or their opioid therapy be discontinued 
causing a withdrawal syndrome.27 HCPs often perceive these 
patients as manipulative.28 It is important, then, to distinguish 
between addiction and pseudo-addiction. A careful clinical 
assessment for objective evidence of pain can decrease the 
risk of being manipulated.
Four common misconceptions of HCPs may result in 
under-treatment of postoperative pain:26
1. Maintenance therapy with buprenorphine or methadone 
provides analgesia.
Patients on maintenance therapy with an opioid ago-
nist require an additional opioid dose for the following 
reasons:
•	 Methadone and buprenorphine effect on pain suppres-
sion is shorter (4–8 hours) than the duration of their 
effect on opioid withdrawal (24–48 hours).17
•	 Due to opioid cross-tolerance, patients require higher 
and more frequent doses of opioid analgesics to 
achieve adequate analgesia.29
•	 OIH may counteract the analgesic effects of 
opioids.30
•	 These patients display increased sensitivity to natural 
and experimental pain. Consequently, pain scores are 
usually higher and decrease more slowly.31,32
2. Additional opioids for analgesia may cause addiction 
relapse.
There is no evidence that analgesic opioids will exac-
erbate addictive disease. Two small studies suggest that 
patients on maintenance methadone programs receiving 
opioids, either for cancer pain33 or for post-surgical pain,34 
showed no relapse when matched with patients receiving 
maintenance methadone therapy only. Conversely, due 
to the potential stress induced, unrelieved pain is a risk 
factor for relapse among the addicted patients.35,36
3. Additional opioids for analgesia may cause respiratory 
and CNS depression.
Clinical experience does not support this concern. 
Conversely, there is evidence that tolerance to opioid-
related respiratory and CNS depression is protective 
in acute or worsening chronic pain. Typically, cancer 
patients who require additional opioids do not exhibit 
drug toxicity when the dose is escalated. Moreover, 
inpatients’ response to opioids can be monitored.37
4. PCA is inadequate for post-surgery analgesia in opioid-
tolerant patients.
There are no specific guidelines available to address 
pain-relief interventions in this specific population. 
Nonetheless, a multimodal approach is recommended.38 
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When regional analgesia is not applicable, a PCA system 
can be considered especially for those who are unable to 
maintain their oral opioids in the perioperative period.39 
Pain scores in opioid-tolerant patients are higher and 
decrease more slowly. Opioid tolerance significantly 
affects analgesic requirements. Unrelieved pain is a risk 
factor for relapse among patients recovering from abuse. 
PCA is the only system which allows to provide patients 
with the right dose of opioid, according to their effective 
needs.40 However, the appropriate setting of bolus size 
and lockout interval may be challenging,41 despite the 
risk of opioid-related respiratory depression being low 
in opioid-tolerant patients.
Perioperative management of 
opioid users for chronic pain
Perioperative management of patients taking opioid therapy 
for chronic pain is very challenging for anesthesiologists. 
This population is at a very high risk of suffering severe 
postoperative pain. Limited application of guidelines in 
real life can be one of the reasons for the high incidence of 
uncontrolled postoperative pain.42
Inadequate postoperative pain management may increase 
pulmonary and cardiovascular complications as well as 
hospital length of stay.43,44 Adequate perioperative manage-
ment is directed to reduce patients’ perioperative anxiety as 
well as postoperative and chronic pain.
Nowadays, evidence on perioperative management of 
opioid users is lacking. Therefore, most information comes 
from expert opinions, more than from clinical trials.
How to treat patients taking 
oral opioids for chronic pain 
management
In patients taking opioids, when significant pain can be 
anticipated, such as after elective surgery, it is helpful 
planning in advance a pain treatment and documenting this 
plan in the medical record, as resumed in the IDEAL five 
steps (Table 3).
It is well recognized that patients should take their usual 
dose of oral opioid on the morning of surgery, with preop-
erative administration of their daily maintenance or baseline 
opioid dose before induction of general, spinal, or regional 
anesthesia.
If the patient cannot receive oral intake (preoperative 
fasting), the oral opioid dose can be converted to the cor-
responding intravenous (IV) dose of morphine:
•	 Determine the total 24-hour dose of the current oral 
opioid.
•	 Calculate the oral morphine equivalent dose (MED) of the 
current opioid, by using equianalgesic tables (Table 4).
•	 Convert the calculated oral MED in IV dose of hydro-
chloride morphine, according to the oral:IV ratio for 
morphine of 3:1.
Opioid rotation allows to reduce the dose by 50% and 
titrate it according to the patient response (the equianalgesic 
dose could be lower than expected because of incomplete 
cross-tolerance).45,46 For example: In a patient taking oral 
oxycodone at 40 mg daily, the equianalgesic oral dose of 
morphine would be 60 mg daily, and the IV dose of mor-
phine sulfate would be 20 mg daily (ie, continuous infusion 
of 0.8 mg/h per 24 hours).
In patients taking the oral combination oxycodone/
naloxone in a ratio 2:1, the effect of the opioid antagonist 
is limited to the gastrointestinal tract, as most of naloxone 
undergoes first pass metabolism in the liver; therefore, only 
2% remains available in the CNS, without any effect on 
analgesia. Also in these patients, the usual oral dose can 
be perioperatively administered if possible. This formula-
tion has also been used as postoperative pain treatment in 
orthopedic surgery.47
intraoperative management
There are no data suggesting the preference for a specific 
intraoperative opioid over another in patients chronically 
treated with opioids or addicted.48 It is impossible to predict 
the level of intraoperative tolerance. The anesthesiologist 
responsible for the patient may select the opioid and titrate 
the doses following the usual method. Usually a parenteral 
infusion is used. The use of remifentanil is controversial 
because of possible acute development of tolerance and 
hyperalgesia.49 Dosage and requirements in different surgical 
settings should be guided by vital signs (heart rate, pupil 
dilation, arterial blood pressure) and, most recently, by 
analgesia nociception index monitoring.50 Usually these 
Table 3 Perioperative treatment plan for opioid-tolerant 
patients
I Identify the problem and specific risk factors
D Define a plan of perioperative pain management, involving 
anesthesiologists, surgeons, nurses, and family members
E Explore possible strategies: use multimodal analgesia and 
regional techniques, when applicable
A Act on the strategies: aggressively treat pain and prevent 
withdrawal
L Look back: evaluate the analgesic effect, functional status, 
and adverse events
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patients need a larger dose of opioids than those commonly 
used for adequate pain control in opioid-naïve patients.51,52 
Regional analgesia may be helpful to reduce intraoperative 
opioid requirements, but does not provide the elimination 
of withdrawal symptoms. Also wound infiltration with local 
anesthetics should be considered. Low dose of ketamine 
(subanesthetic dose) can lead to improved pain scores and 
reduced opioid consumption.16
Postoperative pain
Several studies demonstrated that opioid-dependent patients 
have four-fold increased opioid requirements in the postop-
erative period compared with opioid-naïve patients. Chronic 
opioid users for malignant pain have been reported to use 
three times more epidural morphine and five times more IV 
morphine for breakthrough pain in the postoperative period 
to experience full pain control. Moreover, the duration of 
postoperative treatment is about three times longer in these 
patients compared with opioid-naïve patients.52
Multimodal analgesia is mandatory to reduce opioid 
consumption. Regional analgesia may be useful; however, 
anesthesiologists should consider baseline opioid require-
ments to avoid withdrawal symptoms. PCA may be helpful 
to minimize the risk of under-medication and breakthrough 
pain and to provide equivalent baseline preoperative opioid 
dose.16 There are many advantages in using the PCA sys-
tem: it is easy and immediate to use, provides stable plasma 
levels, ensures pain relief with a lower total opioid consump-
tion, allows fewer interactions between patient and HCPs, 
avoiding anxiety, prejudices and acute withdrawal episodes.48 
A few limitations are present: PCA boluses may be used for 
psychological effects (abuse), and frequent requested doses 
could be perceived as drug craving by HCPs.
Opioid antagonists, including naloxone and naltrexone, 
in opioid users should be avoided. Their use, as well as 
the use of mixed agonist-antagonist-type opioids such as 
nalbuphine, butorphanol, and pentazocine could precipitate 
withdrawal symptoms. These drugs may precipitate acute 
opioid withdrawal in these individuals.
How to treat patients taking 
transdermal opioids for chronic 
pain management
The most commonly used transdermal opioids are fentanyl 
patch (lasting 72 hours) and buprenorphine patch (available 
in two formulations: at higher doses – from 35 µg/h, lasting 
72 hours, and at lower doses – from 5 to 20 µg/h, lasting 
1 week).
The efficacy of full opioid agonists (used for surgical 
pain) could be reduced by the presence of buprenorphine. 
Therefore, if the acute pain episode is anticipated (ie, post-
operative pain after elective surgery), buprenorphine should 
be discontinued 72 hours prior to surgery and conversion to 
a full agonist can be achieved preoperatively.17 
If the acute pain is unanticipated (eg, from trauma) and 
it is not possible to discontinue the buprenorphine, we sug-
gest using an intravenous opioid agonist that binds strongly 
to MOR, such as fentanyl and sufentanil. Higher doses of 
opioids may be necessary to overcome the buprenorphine 
occupation of receptors; hence, very close perioperative 
monitoring is required. The patient will then be discharged 
on full opioid agonist for the control of pain. Reconversion 
to buprenorphine therapy will be done after discharge by the 
pain specialist.17
Conversely, transdermal fentanyl patch should be main-
tained during the surgery. In case this preparation is removed, 
a new patch may then be applied intraoperatively.17 However, 
HCPs should consider that it may take 6–12 hours to re-
establish baseline analgesia; therefore, a baseline IV fentanyl 
infusion may be initiated to maintain plasma concentrations.16 
The only concern about transdermal fentanyl patch is related 
to the risk of altered absorption depending on the type of 
Table 4 equianalgesic doses of opioids
Opioid Approximate oral 
equianalgesic dose
Onset Duration Half-life
Morphine (reference drug)* 30 mg 2–3 h 8–12 h 2–4 h
Tramadol* 150 mg 1–2 h 8–12 h 2–4 h
Codeine (with APAP) 200 mg 30–60 min 4–8 h 3–4 h
Oxycodone* 20 mg 1–2 h 6–10 h 3–4 h
Tapentadol* 100 mg 1–2 h 8–12 h 2–4 h
Hydromorphone# 7.5 mg 12–14 h 20–24 h 8–16 h
Oxymorphone 10 mg 30–45 min 4–6 h 2–3 h
Hydrocodone (with APAP, ASA, or ibuprofen) 30 mg 15–30 min 4–8 h 2–3 h
Notes: *PKs (pharmacokinetics) refer to slow release twice daily (BiD) formulations. #PKs refer to once daily hydromorphone formulation.
Abbreviations: APAP, acetaminophen; ASA, acetylsalicylic acid.
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surgery, amount of administered fluids, and skin tempera-
ture during the procedure. Hypothermia or rewarming may 
affect the kinetics of transdermal fentanyl. Therefore, in the 
case of major surgery, it is preferable to remove the fentanyl 
patch and to administer an equipotent dose of morphine as 
a substitute.48 For example: In a patient taking transdermal 
fentanyl at 25 µg/h (patch change every 72 hours), the 
equianalgesic oral dose of morphine would be 60 mg daily, 
and the IV dose of morphine sulfate would be 20 mg daily 
(ie, continuous infusion of 0.8 mg/h per 24 hours).
How to treat patients taking 
intrathecal opioids for chronic pain 
management
Presence of invasive pain treatment devices (eg, intrathecal 
pumps, spinal cord stimulators) should be investigated as 
additional information in patients with chronic cancer or 
non-cancer pain.53
Continuous epidural and intrathecal opioid infusions, 
delivered by internally implanted devices, can be maintained 
during the surgery as a baseline requirement, compatible with 
the kind of surgery. Caution should be taken if undertaking 
a central block or a surgical procedure near the neuroaxial 
device. Obviously, in the case of spine surgery, it is reason-
able to prescribe the patient with an equivalent dose of IV 
morphine, to guarantee background analgesia for chronic 
pain management.
Perioperative management of 
opioid abusers
In 2016, the American Pain Society (APS) released new 
guidelines for postsurgical pain management, which 
encourage an interdisciplinary approach with routine use 
of nonpharmacological therapies and nonopioid medica-
tions into multimodal analgesia regimens. When a patient 
has opioid tolerance, or a history of substance abuse or 
addiction, APS guidelines recommend to consult a pain 
management specialist. Adequate pain treatment should not 
be withheld from patients with active or previous opioid 
addiction because of fears of worsening addiction or pre-
cipitation of relapse.8
It is important to distinguish clinically between abusers, 
former abusers, and abusers in pharmacological treatment 
with methadone, buprenorphine, or naltrexone.
For abusers, the major problem is related in identifying 
the exact street dose of the abused drugs or other adjuvants, 
to convert these doses to morphine or methadone basal 
daily dose for maintenance during the perioperative phase. 
It is important to obtain as much information about an 
individual’s dependence as possible. Stromer et al suggest 
a basal equivalence between 1 g of heroin and 40–80 mg of 
methadone.49
For former abusers under maintenance treatment 
programs, anesthesiologists should be aware of the drug 
therapy and the timing of the last dose, in order to plan 
adequate perioperative management. Theoretically, any long-
acting oral opioid could be used in the opioid maintenance 
approach, as the goals are to reduce the infective risks of 
IV injections, to decrease craving and rewarding effects, 
and to reduce crimes related to the use of illicit drugs.54 In 
clinical practice, the two most used drugs are methadone and 
buprenorphine, along with naltrexone.
How to manage patients under 
maintenance methadone treatment?
Methadone is a synthetic opioid agonist and N-metyl-D-
aspartate receptor antagonist, which has been used to treat 
opioid dependence since the 1950s.
Methadone is dosed daily in methadone maintenance 
treatment (MMT) because after oral administration, the elimi-
nation half-life averages 15–40 hours and its activity is sig-
nificantly longer than most other opioids.55 By comparison, 
the short-acting heroin (3–6 hours) requires several injections 
during the day while, in MMT, methadone is administered 
only once a day. Conversely, when used for managing acute 
pain, methadone must be dosed TID to QID to adequately 
provide analgesia.26
The maintenance dose of oral methadone begins with 
initial oral doses of 15–30 mg, usually increased to the most 
effective dose between 80 and 120 mg daily. Long-term use 
of MMT dramatically reduces opiate abuse patterns.
Perioperative recommendations for patients in MMT 
include:26
1. If the patient can receive oral intake, he or she should 
continue taking oral methadone on the morning of surgery 
and through all the perioperative period.
2. If the patient is not able to receive oral intake, the metha-
done dose can be given parenterally (intramuscular or 
subcutaneous) at a dose half to two thirds the maintenance 
dose divided into two to four equal doses a day. 
The relative analgesic potency ratio of oral to par-
enteral methadone is 2:1, with wide interindividual 
variability due to pharmacodynamic and PK properties.8,54 
For example: In a patient taking oral methadone at 
80 mg daily, the intramuscular dose would be 10–13 mg 
every 6 hours or 20–26 mg every 12 hours.
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3. If methadone is not available in your hospital, you 
should know practical rules to convert methadone to 
morphine. 
Unfortunately, methadone conversion is challenging for 
prescribers, because conversion calculations may not be bidi-
rectional (ie, the morphine-to-methadone conversion ratio 
may not be the same as the methadone-to morphine ratio). 
As the half-life of methadone is very long, ~15–40 hours, 
it stays in the body for several days after discontinuation. 
Moreover, because methadone is metabolized by CYP450, 
PK parameters and polymorphism of CYP450 may result in 
large interpatient variability in the equianalgesic conversion 
ratio and huge half-life variation (up to 150 hours).56 Finally, 
some drugs such as antidepressants (selective serotonine 
reuptake inhibitors [SSRIs], amitriptyline), antifungals 
(fluconazole, ketoconazole), and macrolide antibiotics 
(erythromycin, clarithromycin) may increase methadone 
concentrations, by inhibiting CYP3A4 metabolism. Con-
versely, other drugs such as antiepileptics (carbamazepine, 
phenobarbital, phenytoin), antipsychotics (risperidone), anti-
retrovirals (nevirapine, ritonavir), anitubercular (rifampin) 
may decrease methadone concentrations.57 Most studies 
investigated the conversion dose ratio in patients being 
prescribed in the opposite manner, that is, from morphine 
to oral methadone, showing that methadone is more potent 
in patients on high-dose opiates. When converting from 
high doses of opiates to methadone, less methadone will be 
required. Conversely, changing from methadone to other 
opioids is still an area of limited research but of increasing 
importance. The estimated dose ratio for IV methadone to 
oral MED is 13.5. The estimated dose ratio for oral metha-
done to oral MED is 4.7. When oral methadone is converted 
to IV morphine sulfate, the estimated dose ratio is 2:1. This 
difference between IV and oral methadone, in terms of MED, 
is not expected based on methadone’s high oral bioavail-
ability, but it appears to be clinically important and likely 
due to presystemic (first pass) elimination. However, this 
ratio may hugely vary depending on patient metabolism. 
Carefully titrate the new opioid, after rotation. Usually 2–3 
days are required to achieve a stable dose. Reassess patients 
at appropriate intervals.58 For example: In a patient taking 
oral methadone at 80 mg daily, the equivalent IV dose of 
morphine would be 40 mg daily. In opioid-naïve patients, 
the IV morphine dose can be reduced to 20–30 mg daily 
(ie, continuous infusion of 1 mg/h or 24 mg per 24 hours), 
only for maintenance therapy. Further doses of morphine 
are required for analgesia.
How to manage patients under 
maintenance buprenorphine treatment?
Buprenorphine has been considered as a partial µ-agonist 
(or a mixed agonist-antagonist) and kappa-antagonist with 
a limited maximum effect (ceiling effect), but other evi-
dence suggests that high doses of buprenorphine bind to 
nociceptin receptor (NOP).59 It is used transdermally for 
chronic pain management and sublingually for long-term 
substitution in opioid abusers. Its effect is estimated from 
24 to .36 hours; therefore, in maintenance programs, 
buprenorphine is dosed once a day or three times a week at a 
higher dose. The initial daily dose of 2–8 mg is increased up 
to 4 mg each week, up to a daily dose as high as 32 mg.54
Available formulations for maintenance programs are:
•	 Sublingual buprenorphine tablets up to 32 mg as a single 
daily dose.
•	 Buprenorphine/naloxone (sublingual tablets) up to 24 mg/ 
6 mg as a single daily dose.
When the combination buprenorphine/naloxone in a 
4:1 ratio is taken sublingually, the opioid antagonist does 
not block the central effect of buprenorphine, because oral 
or sublingual naloxone, as previously described, is rapidly 
inactivated by the liver and its bioavailability results are 
very low.60 
There are several possible approaches for treating severe 
acute pain that requires opioid analgesia in patients under 
buprenorphine maintenance treatment (BMT):26,61
1. We suggest, as a first choice, to continue buprenorphine 
for the BMT and to use a different opioid for analgesia, by 
titrating an oral short-acting (immediate release [IR] mor-
phine or oxycodone) or IV opioid analgesic (morphine 
or fentanyl) to the desired analgesic effect (continuous 
infusions are not recommended). Consider that higher 
doses of opioids could be necessary for competing with 
buprenorphine.
2. Alternatively, if a patient is taking a low maintenance 
dose of buprenorphine (eg, 2–8 mg per day), it can be 
used as analgesic itself. Administer the daily dose of the 
buprenorphine maintenance therapy or a higher dose, if 
necessary, given every 6–8 hours to take advantage of its 
analgesic properties, by increasing its plasma blood level. 
For example: In a patient taking buprenorphine at 32 mg 
daily, the split dose would be 8 mg every 6 hours (QID).
3. Only in patients who cannot be administrated sublingual 
formulations (facial trauma or unconscious patients), we 
propose to discontinue buprenorphine therapy 72 h before 
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surgery and use standard opioids for titration of analgesia. 
Daily doses of opioids must be reassessed every day. 
Buprenorphine, indeed, will persist in the brain for the 
first 3–4 days and the dose of full opioid agonist could 
be higher than expected; while in the following days, the 
opioid dose could be decreased. For example: In a patient 
taking buprenorphine at 32 mg daily, the starting IV dose 
of morphine could be up to 80 mg daily by continuous 
infusion (up to 3 mg/h for 24 hours).
4. Finally, for major surgery, when postoperative pain is 
expected to be high and to require opioid therapy, con-
sider that buprenorphine could act as an antagonist on 
MOR, due to its high affinity and its ceiling effect, and 
prevent the analgesic activity of the full opioid agonist. 
Moreover, buprenorphine has kappa opioid receptor 
antagonist activity that may interfere with the actions of 
other opioids.18 
Therefore, if the risk for relapse is too high, we could 
suggest replacing buprenorphine with methadone a few days 
beforehand, with a ratio of about 1:5 (titrate methadone dose 
by increasing daily methadone doses of 10 to 20 mg incre-
ments every 1–2 hours up to an adequate pain relief).
If time does not permit this conversion, due to unex-
pected events requiring opioid therapy (eg, accidents), 
titration of mu opioids agonist must be aggressive to pro-
vide sufficiently high doses to overcome the buprenorphine 
blockade. For example: In a patient taking buprenorphine at 
32 mg daily, the dose of oral methadone would be 120–150 
mg daily (starting dose 40 mg) or intramuscular (IM) 
methadone 70–80 mg.
How to manage patients under 
maintenance naltrexone treatment?
Naltrexone is an opioid antagonist, used in alcohol-
dependent and opioid-dependent patients. Its efficacy is 
mediated through interactions between dopamine and the 
endogenous opioid neuropeptide systems, also involved in 
the expression of reinforcing effects of alcohol. The new 
once-monthly extended-release formulation of injectable 
naltrexone prevents the relapse to opioid dependence fol-
lowing detoxification.62
Few data are available on perioperative management 
of patients under maintenance naltrexone treatment. These 
patients represent a real challenge for anesthesiologists, 
because naltrexone may cause reduced sensitivity to opi-
oids or precipitate withdrawal symptoms, when re-dosing 
naltrexone soon after opioid use.63 Based on the timing of 
their last naltrexone dose, patients may remain refractory 
or more sensitive to opioids. Within the first 2 weeks, they 
may continue to be refractory to opioid induced analgesia, 
whereas by the fourth week, the opioid receptor antagonism 
may be overcome by using larger doses of opioid agonist than 
in a typical patient. Sometimes, these patients may be more 
sensitive to opioids, because chronic opioid antagonism may 
result in an increased density of opioid receptors in the brain, 
and therefore, they may be more likely to develop the side 
effects and be at risk for significant respiratory depression.
Therefore, we suggest to mainly use nonopioid analge-
sics, such as NSAIDs and acetaminophen, corticosteroids, 
ketamine, and regional analgesic techniques, when indicated. 
Oral naltrexone should be discontinued at least 24–72 hours 
prior, if opioid-based anesthesia is planned.64 When the once-
monthly extended release formulation is used, we might 
suggest planning elective surgery during the fourth week, 
whereas in case of emergency, consider higher doses of 
opioids (identified by titration) and close clinical observation 
in the postoperative care unit for patients under maintenance 
naltrexone treatment.
Conclusion
The number of opioid-tolerant patients requiring acute pain 
treatment is increasing. The management of these patients 
in the perioperative period may be truly a challenge. This 
narrative review describes the view of a panel of experts 
on what the practicing clinicians (anesthesiologist, surgeon, 
or other HCPs) should know about the perioperative pain 
management of opioid-tolerant patients. Universal agree-
ment on the management of these patients, particularly those 
under maintenance treatment, is lacking. A short list of key 
messages is reported as a Decalogue in the following box. 
The effective pain management of patients with an addic-
tive disorder requires a comprehensive multidisciplinary 
approach that encompasses biological, pharmacological, 
social, and psychiatric aspects of a complex CNS disorder. 
Decalogue of good practice for perioperative pain manage-
ment of opioid users and abusers:
 1. Identify opioid user and abusers
 2. Consider comorbidities
 3. Consider the pharmacological and psychological dif-
ferences present in such patients
 4. Guarantee baseline requirements of opioids, regardless 
of the anesthetic technique
 5. Prefer local and regional analgesia techniques when 
suitable
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 6. Do not restrict opioid treatment in these patients
 7. Provide effective analgesia and treat pain aggressively
 8. Prefer multimodal analgesia
 9. Do not induce weaning or OIH in the perioperative 
period
 10. Do not give any unsuitable judgment regarding patient 
addiction.
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